Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy-Reference-Cited by-同舟云学术

Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy

Published:2021-12-02 Issue:2 Volume:165 Page:234-249
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Herrera Lara¹²,Martin‐Inaraja Myriam¹²,Santos Silvia¹²,Inglés‐Ferrándiz Marta¹²,Azkarate Aida¹²,Perez‐Vaquero Miguel A.¹²,Vesga Miguel A.¹²,Vicario Jose L.³,Soria Bernat⁴⁵,Solano Carlos⁶⁷,De Paz Raquel⁸,Marcos Antonio⁸,Ferreras Cristina⁹,Perez‐Martinez Antonio⁹¹⁰¹¹,Eguizabal Cristina¹²^ORCID

Affiliation:

1. Research Unit Basque Center for Blood Transfusion and Human Tissues Osakidetza, Galdakao Spain

2. Cell Therapy, Stem Cells and Tissues Group Biocruces Bizkaia Health Research Institute Barakaldo Spain

3. Histocompatibility Centro de Transfusión de Madrid Madrid Spain

4. Instituto de Bioingeniería Universidad Miguel Hernández de Elche Alicante Spain

5. Instituto de Investigación Sanitaria Hospital General y Universitario de Alicante (ISABIAL) Alicante Spain

6. Hospital Clínico Universitario de Valencia/Instituto de Investigación Sanitaria INCLIVA Valencia Spain

7. School of Medicine University of Valencia Spain

8. Hematology Department University Hospital La Paz Madrid Spain

9. Hospital La Paz Institute for Health Research IdiPAZ University Hospital La Paz Madrid Spain

10. Pediatric Hemato‐Oncology Department University Hospital La Paz Madrid Spain

11. Faculty of Medicine Universidad Autónoma de Madrid Madrid Spain

Funder

Instituto de Salud Carlos III

Fundación Mutua Madrileña

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13432

Reference76 articles.

1. WHO.Coronavirus disease (COVID‐19) outbreak situation reports(available athttps://www.who.int/emergencies/diseases/novel‐coronavirus‐2019

2. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

3. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis

4. Treatment for COVID-19: An overview

5. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant human interleukin-2 corrects NK cell phenotype and functional activity in patients with post-COVID syndrome;Cytokines and inflammation;2024-09-04

2. The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients’ survival and long COVID;Frontiers in Immunology;2024-07-29

3. A Phase I, Dose-Escalation Clinical Trial to Evaluate the Safety of Infusing Natural Killer Cells as Adoptive Therapy in COVID-19: Release;2024

4. Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1;Scientific Reports;2023-11-03

5. NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?;Frontiers in Immunology;2023-10-19